Valproate in the treatment of epilepsy and status epilepticus

Antiepileptic property of valproate was discovered in ۱۹۶۲, when it was tested as a solvent for other molecules being checked for anticonvulsant activity. It has the broadest spectrum of anticonvulsant action compared to all currently available antiepileptic drugs (AEDs), both in adults and children. It has epigenetic effect in several fields specially cancer treatment. Pharmacodynamics of valproate: enhances GABA synthesis and release, reduces the release of the excitatory molecules (NMDA) and blockade of voltage gated ionic channels.Valproate is effective against all the types of seizure and epileptic syndromes, both in pediatric and adult patients. In particular, it has been tested in both generalized (tonic-clonic, absences and myoclonic) and focal seizures, and it has been found effective in Lennox-Gastaut, West and Dravet syndrome.The efficacy, safety and tolerability of intravenous (IV) valproate has also been evaluated in the management of generalized convulsive status epilepticus. Valproate has Supra additive effect in some combination of antiseizure medicines.